Download Slide 1 - Educational Concepts Group

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Educational Objectives
Metastatic Breast Cancer: Scope of
the Problem
Metastatic Breast Cancer: General
Treatment Considerations
Therapeutic Goals/Endpoints in
MBC
MBC: Impact of Chemotherapy
Treatment Options for Advanced
Breast Cancer
First-Line Chemotherapy Options
Response Rates with Single-Agent
Chemotherapeutic Agents in MBC
Highlights of the Evolution of
Taxanes in Oncology
Taxanes in the Treatment of MBC
Conventional Taxanes:
Pharmacologic and
Pharmacodynamic Differences
Conventional Taxanes: Impact of
Solvents
Albumin Role: Natural Carrier of
Hydrophobic Molecules in Humans
Increased Intratumoral
Concentration With nab-Paclitaxel
Differentiating the Taxanes: Toxicity
Making Taxanes Less “Tax-ing”
Taxane Toxicities
Randomized Comparison Between
Taxanes
Taxanes: Premedication Guidelines
Taxane Hypersensitivity Reactions
Anemia
Differentiating the Taxanes:
Efficacy
Pivotal Phase III Trials of Paclitaxel
Single Agent and Combinations
Pivotal Phase III Trials of Docetaxel
Single Agent and Combinations
TAX 311: Paclitaxel versus
Docetaxel in Metastatic Breast
Cancer
TAX 311: Paclitaxel Versus
Docetaxel in Metastatic Breast
Cancer – OS
TAX 311: Hematologic Toxicity
TAX 311: Non-Hematologic Toxicity
TAX 311: Quality of Life Analysis
Phase III Trial of nab-Paclitaxel vs
Paclitaxel in MBC: Design
Phase III Trial of nab-Paclitaxel vs
Paclitaxel in MBC: Results
Phase III Trial of nab-Paclitaxel vs
Paclitaxel in MBC: TTP
Phase III Trial of nab-Paclitaxel vs
Paclitaxel in MBC: OS
Phase III Trial of nab-Paclitaxel vs
Paclitaxel in MBC: OS ( ≥ 2nd-line
Patients)
nab-Paclitaxel vs Paclitaxel in
MBC: Hematologic Toxicities
nab-Paclitaxel vs Paclitaxel in
MBC: Non-Hematologic Toxicities
nab-Paclitaxel vs Paclitaxel in
MBC: Neuropathy Resolution
Phase II Study of Weekly nabPaclitaxel in Taxane-Refractory
MBC
Taxanes: Cost-effectiveness Model
Cost-effectiveness Model:
Methodology (cont.)
Costs per Cycle
Frequency of Grade 3/4 Toxicities
(O’Shaughnessy 2003)
Treatment Costs per Toxicity for
Taxane Therapy
Cost-effectiveness Ratios
Model Analysis of Total Costs
Conclusions
Related documents